Ignite Creation Date:
2025-12-24 @ 11:53 PM
Ignite Modification Date:
2026-02-25 @ 8:17 PM
Study NCT ID:
NCT00881751
Status:
COMPLETED
Last Update Posted:
2017-09-11
First Post:
2009-04-14
Is Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Bevacizumab and Erlotinib or Sorafenib as First-Line Therapy in Treating Patients With Advanced Liver Cancer
Sponsor:
Medical University of South Carolina
Organization:
Organization Data
Organization:
Class:
OTHER
Study ID:
101282
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
OTHER
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None